United Therapeutics (UTHR) CEO Rothblatt Sells $5.2M of Stock
United Therapeutics Corporation Chairperson and CEO Martine Rothblatt sold 9,500 shares of stock on October 15, 2026, for about $5.2 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Martine A Rothblatt, Chairperson & CEO at United Therapeutics Corporation ($UTHR), sold 9,500 shares at an average price of $546.65, worth about $5.19 million, on October 15, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $UTHR is down 1.6% to date (from the $541.51 close on Oct 15, 2026).
UTHR
United Therapeutics Corporation
Key Points
- United Therapeutics Chairperson and CEO Martine Rothblatt sold 9,500 shares for approximately $5.2 million on October 15, 2026, according to a Form 4 filing with the SEC.
- After the trade, Martine A Rothblatt indirectly holds 324,443 $UTHR shares, down 2.84% from before the trade.
- The stock recently traded around $541.98, sitting above its 50-day and 200-day moving averages as the company prepares for its upcoming earnings report on October 28, 2026.
- Major institutional investors including Avoro Capital Advisors and Renaissance Technologies adjusted their positions in the drug developer earlier in the year.
Get $UTHR trade alerts by text
We text you when insiders, Congress or big funds trade $UTHR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated United Therapeutics Corporation alert may contain errors. Disclosures
United Therapeutics Corporation Chairperson and CEO Martine Rothblatt sold 9,500 shares of the company on October 15, 2026, for a total value of about $5.2 million. According to a Form 4 filed with the SEC, the transaction was executed at an average price of $546.65 under a pre-arranged Rule 10b5-1 trading plan.
Inside Martine A Rothblatt's United Therapeutics Trade
The CEO's sale on October 15, 2026, followed four identical sales of 9,500 shares each executed earlier in October. Following this latest transaction, Rothblatt directly held 324,443 shares of United Therapeutics, marking a 2.84% reduction in total personal holdings. The stock closed at $541.51 on the day of the trade.
Other Institutional Activity in United Therapeutics
Avoro Capital Advisors LLC grew its holdings by 147,804 shares, ending with 2,777,777 shares worth about $1.48 billion. Renaissance Technologies, LLC trimmed its position by 78,271 shares to hold 1,708,739 shares valued at $910.96 million. Jupiter Topco LLC increased its stake by 415,564 shares, a 100.0% rise that brought its total to 831,129 shares worth about $443.09 million.
United Therapeutics Corporation Stock Up 0.1%
The shares recently traded around $541.98 as of October 17, 2026, putting the price up about 5.3% above its 50-day moving average of $514.66 and 2.9% above its 200-day moving average of $526.82. The stock trades about 11.1% below its 52-week high of $609.35 and 32.5% above its 52-week low of $409.07.
Recent Earnings
United Therapeutics reported trailing twelve month revenue of $3.15 billion and earnings of $27.92 per share. The company generated a net profit margin of 41.6% and a return on equity of 19.3%. Investors will monitor the upcoming earnings report on October 28, 2026, for further financial updates.
Insider Buying and Selling at United Therapeutics Corporation
Insiders executed multiple planned sales during October 2026, including four prior transactions by CEO Martine Rothblatt and a sale by executive Paul A. Mahon. These routine transactions were carried out pursuant to pre-arranged trading plans adopted well in advance.
Analysts Set New Price Targets
Wall Street firms have adjusted their views on the stock recently, including RBC Capital maintaining an Outperform rating with a $708 target on October 8, 2026, and Morgan Stanley maintaining an Equal-Weight rating with a $566 target on October 7, 2026. Overall, analysts hold a consensus buy recommendation with a mean price target of $656.93.
About United Therapeutics
United Therapeutics is a healthcare company based in Silver Spring, Maryland, focused on developing specialty therapeutics for patients dealing with severe chronic illnesses. The firm relies on its biotechnology pipeline to address critical medical needs in cardiology and other therapeutic areas.
Bottom Line
With earnings scheduled for October 28, 2026, market participants continue to track insider transactions and institutional portfolio shifts closely.
Related Filing Alerts
Source: Martine A Rothblatt's Form 4 filing on $UTHR (Oct 15, 2026). Read the original filing: Form 4 filing on SEC EDGAR. Written by software, not financial advice. How we make alerts